Lifemd, Inc. insider trading

Every open-market purchase and sale by Lifemd, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $0 0 trades by 0 insiders Insider sales, 5 years $54,150 1 trade by 1 insider 3 months later: median +7.7% (+8.3% vs S&P 500)

No insider has bought shares on the open market in five years.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Lifemd, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Lifemd, Inc.’s insiders pay?

From October 27, 2017 to December 11, 2025, 13 insiders reported 42 open-market purchases and 6 sales not made under a pre-set plan in Lifemd, Inc. Twelve months after each purchase was reported, the shares were −69.2% against the S&P 500 on average (median −76.6%), over 16 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −68.2% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 26, 2021 into $3,502 by November 2, 2026, −16.9% a year. It held shares 41% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $13,034 (+4.8% a year), and held throughout $21,472 (+14.4%).

Copying Lifemd, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Lifemd, Inc.'s insiders from February 26, 2021, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 41% of the time.

Lifemd, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Schreiber Justin	CEO	8	−76.6% (1)	0%	0	—	May 24, 2023
Velge Bertrand	Director	6	—	—	0	—	August 31, 2023
Yecies Eric Harold	Chief Legal Officer & GC	5	−89.2% (2)	0%	1	−97.7% (1)	June 17, 2025
Deutsch Corey	Chief Business Officer	5	−67.8% (5)	0%	0	—	August 25, 2021
Galluppi Stefan	Chief Innovation Officer	3	−40.0% (2)	0%	1	—	September 12, 2024
Walters Happy David	Other	4	−57.2% (1)	0%	0	—	September 15, 2021
Benathen Marc David	Chief Financial Officer	3	−70.3% (2)	0%	0	—	December 1, 2021
Bhatia Naveen	Director	3	—	—	0	—	May 19, 2022
Alvarez Nicholas P	Chief Acquisition Officer	1	—	—	1	−60.3% (1)	September 12, 2025
Ditrolio Joseph	Director	2	−67.6% (2)	0%	0	—	August 19, 2021
Friedeman Jessica	Chief Marketing Officer	0	—	—	2	−46.6% (1)	December 11, 2025
Roberts Brad Michael	Chief Operating Officer	2	−100.4% (1)	0%	0	—	May 30, 2023
Mclaughlin Mark	10% owner	0	—	—	1	—	February 20, 2018

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Lifemd, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Lifemd, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −83.1% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
February 26, 2021	2 buying	−55.3%	−83.1%	−100.4%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Lifemd, Inc. · Funds · Politicians